Arformoterol tartrate inhalation solution

DRUG8 trials

Sponsors

Sumitomo Pharma America, Inc.

Conditions

BronchitisCOPDChronic BronchitisChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease (COPD)Emphysema

Phase 2

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00685529

Sumitomo Pharma America, Inc.COPD

Start: 2005-04-30End: 2005-10-31Updated: 2012-02-22

A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00691405

Sumitomo Pharma America, Inc.COPD

Start: 2003-10-31End: 2004-05-31Updated: 2012-02-22

Phase 3

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

CompletedNCT00064402

Sumitomo Pharma America, Inc.Chronic Bronchitis, Chronic Obstructive Pulmonary Disease, Emphysema

Start: 2002-04-30End: 2004-03-31Updated: 2012-02-22

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

CompletedNCT00250679

Sumitomo Pharma America, Inc.Bronchitis, Chronic Obstructive Pulmonary Disease, Emphysema

Start: 2005-10-31End: 2007-10-31Updated: 2012-06-04

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00685841

Sumitomo Pharma America, Inc.COPD

Start: 2002-02-28End: 2003-06-30Updated: 2012-11-02

Phase 4

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

CompletedNCT00424528

Sumitomo Pharma America, Inc.Bronchitis, Chronic Obstructive Pulmonary Disease, Emphysema

Start: 2006-12-31End: 2007-10-31Updated: 2012-06-04

Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

CompletedNCT00571428

Sumitomo Pharma America, Inc.Chronic Obstructive Pulmonary Disease

Start: 2007-11-30End: 2008-03-31Updated: 2012-02-22

A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

TerminatedNCT02275481

Sumitomo Pharma America, Inc.Chronic Obstructive Pulmonary Disease (COPD)

Start: 2014-11-30End: 2016-09-14Updated: 2018-06-27

Related Papers

Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.

2009-08-014 citations